Home
>
US Stocks
>
Chinook Therapeutics Inc
Chinook Therapeutics Inc
KDNY

Chinook Therapeutics Inc (KDNY)

$10.750.56%

  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open$10.75
Today Low/High$10.73 / $10.94
52 Week Low/High$10.48 / $21.68
Market Cap$478.91M

Company Details

Chinook Therapeutics, Inc. is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Chinook's product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook's lead program is atrasentan, an investigational phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a phase 1b trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an investigational oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases, including polycystic kidney disease. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways.
OrganisationChinook Therapeutics Inc
HeadquatersBerkeley, California, US
Employees105
IndustryHealth Technology
CEOStephen Isaacs

Discover more

Frequently Asked Questions

What is Chinook Therapeutics Inc (KDNY) share price today?

Can Indians buy Chinook Therapeutics Inc (KDNY) shares?

How can I buy Chinook Therapeutics Inc (KDNY) shares from India?

Can Fractional shares of Chinook Therapeutics Inc (KDNY) be purchased?

What are the documents required to start investing in Chinook Therapeutics Inc (KDNY) stocks?

We are a SEBI registered investement advisor